Synthesis and biological evaluation of 2-substituted-5-(4- nitrophenylsulfonamido)benzoxazoles as human GST P1-1 inhibitors, and description of the binding site features

ChemMedChem

Volumn 9, Issue 5, 2014, Pages 984-992

  Ertan Bolelli, Tuǧba ^a   Musdal, Yaman ^b   Bolelli, Kayhan ^a   Yilmaz, Serap ^a   Aksoy, Yasemin ^b   Yildiz, Ilkay ^a   Aki Yalcin, Esin ^a   Yalcin, Ismail ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

benzoxazoles; glutathione; glutathione S transferase; molecular modeling; sulfonamides

Indexed keywords

2 (4 CHLOROBENZYL) 5 (4 NITROPHENYLSULFONAMIDO)BENZOXAZOLE; AMIDASE; ANTINEOPLASTIC AGENT; BENZOXAZOLE DERIVATIVE; ETACRYNIC ACID; GLUTATHIONE; GLUTATHIONE S TRANSFERASE P1 1; GLUTATHIONE S TRANSFERASE P1 1 INHIBITOR; GLUTATHIONE TRANSFERASE P1; ISOENZYME; NITRO DERIVATIVE; PRODRUG; SULFONAMIDASE; SULFONAMIDE; UNCLASSIFIED DRUG; XENOBIOTIC AGENT; ENZYME INHIBITOR; GLUTATHIONE TRANSFERASE;

ARTICLE; CHEMICAL BOND; CONJUGATE; CYTOSOL; DETOXIFICATION; DRUG BINDING SITE; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ELECTROPHILICITY; ENZYME INHIBITION; ENZYME MECHANISM; HYDROLYSIS; IC 50; MOLECULAR DOCKING; MULTIDRUG RESISTANCE; NUCLEOPHILICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REACTION ANALYSIS; SUBSTITUTION REACTION; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HUMAN; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

BENZOXAZOLES; BINDING SITES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GLUTATHIONE TRANSFERASE; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84899978429     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201400010     Document Type: Article

References (48)

1. N. Mathew, M. Kalyanasundaram, K. Balaraman, Expert Opin. Ther. Pat. 2006, 16, 431-444.
2. J. D. Hayes, J. U. Flanagan, I. R. Jowsey, Annu. Rev. Pharmacol. Toxicol. 2005, 45, 51-88.
3. I. Meijerman, J. H. Beijnen, J. H. Schellens, Cancer Treat. Rev. 2008, 34, 505-520.
4. R. N. Armstrong, Chem. Res. Toxicol. 1997, 10, 2-18.
5. T. Kano, M. Sakai, M. Muramatsu, Cancer Res. 1987, 47, 5626-5630.
6. S. Kazemnejad, Y. Rasmi, R. Sharifi, A. Allameh, Iran. J. Biotechnol. 2006, 4, 1-16.
7. D. M. Townsend, K. D. Tew, Oncogene 2003, 22, 7369-7375.
8. A. Sau, F. P. Trengo, F. Valentino, G. Federici, A. M. Caccuri, Arch. Biochem. Biophys. 2010, 500, 116-122.
9. K. D. Tew, S. Dutta, M. Schultz, Adv. Drug Delivery Rev. 1997, 26, 91-104.
10. I. Quesada-Soriano, L. J. Parker, A. Primavera, J. M. Casas-Solvas, A. Vargas-Berenguel, C. Barõn, C. J. Morton, A. P. Mazzetti, M. Lo Bello, M. W. Parker, L. García-Fuentes, Protein Sci. 2009, 18, 2454-2470.
11. S. Tsuchida, K. Sato, Crit. Rev. Biochem. Mol. Biol. 1992, 27, 337-384.
12. D. J. Waxman, Cancer Res. 1990, 50, 6449-6454.
13. J. C. Schisselbauer, R. Silber, E. Papadopoulos, K. Abrains, F. P. LaCreta, K. D. Tew, Cancer Res. 1990, 50, 3562-3568.
14. V. Adler, Z. Yin, S. Y. Fuchs, M. Benezra, L. Rosario, K. D. Tew, M. R. Pincus, M. Sardana, C. J. Henderson, C. R. Wolf, R. J. Davis, Z. Ronai, EMBO J. 1999, 18, 1321-1334.
15. Z. Zhao, K. A. Koeplinger, T. Peterson, R. A. Conradi, P. S. Burton, A. Suarato, R. L. Heinrikson, A. G. Tomasselli, Drug Metab. Dispos. 1999, 27, 992-998.
16. K. A. Koeplinger, Z. Zhao, T. Peterson, J. W. Leone, F. S. Schwende, R. L. Heinrikson, A. G. Tomasselli, Drug Metab. Dispos. 1999, 27, 986-991.
17. I. Axarli, N. E. Labrou, C. Petrou, N. Rassias, P. Cordopatis, Y. D. Clonis, Eur. J. Med. Chem. 2009, 44, 2009-2016.
18. Y. Kodera, S. Akiyama, K. Isobe, K. Kondo, K. Ito, M. Yamauchi, H. Takagi, Eur. J. Cancer 1994, 30A, 2158-2162.
19. M. Prudhomme, J. Guyot, G. Jeminet, J. Antibiot. 1986, 39, 934-937.
20. D. Díez-Martin, N. R. Kotecha, S. V. Ley, S. Mantegani, J. C. Menendez, H. M. Organ, A. D. White, B. J. Banks, Tetrahedron 1992, 48, 7899-7938.
21. I. Yalcin, I. Ören, E. Sener, A. Akin, N. Ucartürk, Eur. J. Med. Chem. 1992, 27, 401-406.
22. I. Oren, O. Temiz, I. Yalcin, E. Sener, A. Akin, N. Ucarturk, Arzneim.-Forsch./Drug Res. 1997, 47, 1393-1397.
23. O. Temiz, I. Oren, E. Sener, I. Yalcin, N. Ucarturk, Farmaco 1998, 53, 337-341.
24. I. Ören, O. Temiz, I. Yalcin, E. Sener, N. Altanlar, Eur. J. Pharm. Sci. 1998, 7, 153-160.
25. O. Temiz-Arpaci, I. Oren, N. Altanlar, Farmaco 2002, 57, 175-181.
26. Ö. Temiz-Arpaci, E. Aki-Sener, I. Yalcin, N. Altanlar, Farmaco 2002, 57, 771-775.
27. I. Yildiz-Oren, I. Yalcin, E. Aki-Sener, N. Ucarturk, Eur. J. Med. Chem. 2004, 39, 291-298.
28. I. Yildiz-Oren, B. Tekiner-Gulbas, I. Yalcin, O. Temiz-Arpaci, E. Aki-Sener, N. Altanlar, Arch. Pharm. 2004, 337, 402-410.
29. Ö. Temiz-Arpaci, A. Özdemir, I. Yalcin, I. Yildiz, E. Aki-Sener, N. Altanlar, Arch. Pharm. 2005, 338, 105-111.
30. A. Akbay, I. Oren, O. Temiz-Arpaci, E. Aki-Sener, I. Yalcin, Arzneim.-Forsch./Drug Res. 2003, 53, 266-271.
31. R. K. Plemper, K. J. Erlandson, A. S. Lakdawala, A. Sun, A. Prussia, J. Boonsombat, E. Aki-Sener, I. Yalcin, I. Yildiz, O. Temiz-Arpaci, B. P. Tekiner, D. Liotta, J. P. Snyder, Proc. Natl. Acad. Sci. USA 2004, 101, 5628-5633.
32. H. Lage, E. Aki-Sener, I. Yalcin, Int. J. Cancer 2006, 119, 213-220.
33. A. Pbox drawings light down and leftnar, P. Yurdakul, I. Yildiz-Oren, O. Temiz-Arpaci, N. L. Acan, E. Aki-Sener, I. Yalcin, Biochem. Biophys. Res. Commun. 2004, 317, 670-674.
34. O. Temiz-Arpaci, B. Tekiner-Gulbas, I. Yildiz, E. Aki-Sener, I. Yalcin, Bioorg. Med. Chem. 2005, 13, 6354-6359.
35. B. Tekiner-Gulbas, O. Temiz-Arpaci, I. Yildiz, E. Aki-Sener, I. Yalcin, SAR QSAR Environ. Res. 2006, 17, 121-132.
36. E. Şener, İ. Yalçbox drawings light down and leftn, S. Özden, T. Özden, A. Akbox drawings light down and leftn, S. Ybox drawings light down and leftldbox drawings light down and leftz, Turk. J. Med. Pharm. 1987, 11, 391-396.
37. G. M. Wynne, S. P. Wren, P. D. Johnson, P. D. Price, O. De Moor, G. Nugent, R. Storer, R. J. Pye, C. R. Dorgan, (Vastox PLC), Int. PCT Pub. No. WO 2007/091106 A2, 2007.
38. G. M. Wynne, S. P. Wren, P. D. Johnson, P. D. Price, O. De Moor, G. Nugent, R. Storer, R. J. Pye, C. R. Dorgan, US Pat. Appl. No. US 2009/075938 A1, 2009.
39. X. Zheng, H. Oda, K. Takamatsu, Y. Sugimoto, A. Tai, E. Akaho, H. I. Ali, T. Oshiki, H. Kakuta, K. Sasaki, Bioorg. Med. Chem. 2007, 15, 1014-1021.
40. B. Wu, D. Dong, Trends Pharmacol. Sci. 2012, 33, 656-668.
41. Y. Musdal, T. Ertan-Bolelli, K. Bolelli, S. Yilmaz, D. Ceyhan, U. Hagazy, B. Mannervik, Y. Aksoy, Turk. J. Biochem. 2012, 37, 431-436.
42. A. Karshikoff, P. Reinemer, R. Huber, R. Ladenstein, Eur. J. Biochem. 1993, 215, 663-670.
43. A. J. Oakley, J. Rossjohn, M. Lo Bello, A. M. Caccuri, G. Federici, M. W. Parker, Biochemistry 1997, 36, 576-585.
44. S. Mahajan, W. M. Atkins, Cell. Mol. Life Sci. 2005, 62, 1221-1233.
45. R. H. Kolm, G. Stenberg, M. Widersten, B. Mannervik, Protein Expression Purif. 1995, 6, 265-271.
46. R. H. Kolm, U. H. Danielson, Y. Zhang, P. Talalay, B. Mannervik, Biochem. J. 1995, 311, 453-459.
47. Discovery Studio 3.5, Accelrys Inc., 2012.
48. G. Wu, D. H. Robertson, C. L. Brooks III, M. Vieth, J. Comput. Chem. 2003, 24, 1549-1562.